Amount of eligible patients: CDEC reviewed the uncertainty in the volume of clients with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some patients that are labeled as having gentle or moderate disorder could possibly have a serious bleeding https://hemgenix84936.popup-blog.com/34740718/the-smart-trick-of-hemgenix-that-nobody-is-discussing